GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan Hvsen Biotechnology Co Ltd (SZSE:300871) » Definitions » EBIT

Wuhan Hvsen Biotechnology Co (SZSE:300871) EBIT : ¥-18 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Wuhan Hvsen Biotechnology Co EBIT?

Wuhan Hvsen Biotechnology Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥16 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-18 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Wuhan Hvsen Biotechnology Co's annualized ROC % for the quarter that ended in Sep. 2024 was 0.91%. Wuhan Hvsen Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Wuhan Hvsen Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -0.27%.


Wuhan Hvsen Biotechnology Co EBIT Historical Data

The historical data trend for Wuhan Hvsen Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hvsen Biotechnology Co EBIT Chart

Wuhan Hvsen Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 80.35 178.33 153.71 75.09 40.66

Wuhan Hvsen Biotechnology Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.48 9.40 -11.14 -32.04 16.16

Competitive Comparison of Wuhan Hvsen Biotechnology Co's EBIT

For the Biotechnology subindustry, Wuhan Hvsen Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Hvsen Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan Hvsen Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Wuhan Hvsen Biotechnology Co's EV-to-EBIT falls into.


;
;

Wuhan Hvsen Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Hvsen Biotechnology Co  (SZSE:300871) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Wuhan Hvsen Biotechnology Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=15.644 * ( 1 - -22.43% )/( (2082.655 + 2116.253)/ 2 )
=19.1529492/2099.454
=0.91 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2941.071 - 404.932 - ( 556.055 - max(0, 781.534 - 1235.018+556.055))
=2082.655

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2912.533 - 480.099 - ( 469.583 - max(0, 893.126 - 1209.307+469.583))
=2116.253

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Wuhan Hvsen Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=64.648/( ( (1546.794 + max(209.948, 0)) + (1547.832 + max(160.236, 0)) )/ 2 )
=64.648/( ( 1756.742 + 1708.068 )/ 2 )
=64.648/1732.405
=3.73 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(316.777 + 288.951 + 32.975) - (404.932 + 0 + 23.823)
=209.948

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(350.457 + 251.244 + 67.13) - (480.099 + 0 + 28.496)
=160.236

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Wuhan Hvsen Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-17.61/6431.130
=-0.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Hvsen Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Wuhan Hvsen Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Hvsen Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
218 Zhangbai Road, Dongxihu District, Hubei Province, Wuhan, CHN, 430042
Wuhan Hvsen Biotechnology Co Ltd is engaged in research and development, production and sales of veterinary drugs (including chemical drug preparations, raw materials, and Chinese medicine preparations), feed and additives. It produces tylvalosin raw material, various tylvalosin preparations, florfenicol preparations and other macrolides products.

Wuhan Hvsen Biotechnology Co Headlines

No Headlines